Drug-nutrient interaction in clinical nutrition

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 5, Issue 3, 2002, Pages 327-332

  Chan, Lingtak Neander ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CALCIUM; CATION; CIPROFLOXACIN; CYCLOSPORIN; CYTOCHROME P450 3A4; FELODIPINE; FOLIC ACID; LEVOFLOXACIN; MAGNESIUM; OFLOXACIN; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; WARFARIN;

CLINICAL PRACTICE; DIETARY INTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG NUTRIENT INTERACTION; ENTERIC FEEDING; ENZYME INHIBITION; FOLIC ACID DEFICIENCY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; NUTRIENT; NUTRITIONAL SUPPORT; PRACTICE GUIDELINE; REVIEW; BIOAVAILABILITY; DRUG EFFECT; INTESTINE ABSORPTION; PHARMACOKINETICS; TREATMENT OUTCOME;

BIOLOGICAL AVAILABILITY; ENTERAL NUTRITION; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; PHARMACOKINETICS; TREATMENT OUTCOME;

EID: 0036583015     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200205000-00014     Document Type: Review

References (28)

1. Chan L-N. Redefining drug-nutrient interactions. Nutr Clin Pract 2000; 15:249-252.
2. Crowther RS, Bellanger R, Szauter KEM. In vitro stability of ranitidine hydrochloride in enteral nutrient formulas. Ann Pharmacother 1995; 29:859-862.
3. Lourenco R. Enteral feeding: drug/nutrient interaction. Clin Nutr 2001; 20:187-193. A precise overall review of the potential consequences of drug-nutrient interactions in patients receiving enteral feeding. An exceptional overview is provided of the keys factors that need to be taken into consideration in patients undergoing enteral feeding in order to minimize the interactions. A step-by-step recommendation is also given on administering drugs during continuous enteral feeding.
4. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37:213-255.
5. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29:413-580.
6. Reuss L. One-hundred years of inquiry: the mechanism of glucose absorption in the intestine. Ann Rev Physiol 2000; 62:939-946. An excellent review on the history of the discovery of the intestinal glucose transport mechanism. Some of the transporters may have potential implications for drug-nutrient interactions.
7. Barany E, Sperber E. Absorption of glucose against a concentration gradient by the small intestine of the rabbit. Scand Arch Physiol 1939; 81:290-299.
8. Kraehenbuhn JP, Pringault E, Neutra MR. Intestinal epithelia and barrier functions. Aliment Pharmacol Ther 1997; 11 (Suppl 3):3-8.
9. Yang CY, Dantzig AH, Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharm Res 1999; 16:1331-1343.
10. Koepsell K. Organic cation transporters in intestine, kidney, liver, brain. Ann Rev Physiol 1998; 60:243-266.
11. Van Asperen J, Van Telligen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998; 37:429-435.
12. Bailey DG, Malcom J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46:101-110.
13. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99:2545-2553.
14. Mueller BA, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994; 38:2101-2105.
15. Howard PA, Hannaman KN. Warfarin resistance linked to enteral nutrition products. J Am Diet Assoc 1985; 85:713-715.
16. Maka DA, Murphy LK. Drug-nutrient interactions: a review. AACN Clin Issues 2000; 11:580-589.
17. Martin JE, Lutomski DM. Warfarin resistance and enteral feeding. JPEN J Parenter Enteral Nutr 1989; 13:206-208.
18. Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil 2001; 82:1270-1273. One of the best mini-studies, exploring the mechanism of warfarin-enteral feeding interaction. Two cases are presented that show how enteral feeding affected the pharmacodynamic effects of warfarin. A follow-up in-vitro study using the exact enteral feeding formulas was conducted in an attempt to explain the mechanism of interaction. The in-vitro study implied that the protein content, rather than the vitamin K content, in the feeding formulas was responsible for the interaction.
19. Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. Ann Pharmacother 1991; 25:1249-1258.
20. Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989; 87(Suppl 5A):67S-81S.
21. Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enteral Nutr 2000; 24:42-48. This study aimed to determine if mixing fluoroquinolone antibiotics with common enterai feeding formulas would lead to a decrease in the fluoroquinolone concentrations after a 24 hour in-vitro incubation. The quinolones tested were ciprofloxacin, ofloxacin, and levofloxacin. The results were compared with controls (mixing the antibiotics in water, magnesium chloride solution, calcium chloride solution, and magnesium and calcium chloride solution). The findings indicate that there was an immediate and significant loss of fluoroquinolone when mixed with enterai formulas. The same effect, however, was not observed after mixing fluoroquinolone with cationic solutions (magnesium, calcium). It is suggested that chelation by cations cannot fully explain the magnitude of this drug-nutrient interaction.
22. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32:570-572.
23. Au Yeung SC, Ensom MHH. Phenytoin and enteral feedings: does evidence support an interaction? Ann Pharmacother 2000; 34:896-905. This is an exceptional review of the evidence that supports or refutes the interaction between phenytoin and enteral feeding. Includes a thorough discussion on the pros and cons of each study and case report.
24. Lewis DP, Van Dyke DC, Willhite LA, et al. Phenytoin-folie acid interaction. Ann Pharmacother 1995; 29:726-735.
25. Seligmann H, Potasman I, Weller B, et al. Phenytoin-folic acid interaction: a lesson to be learned. Clin Neuropharmacol 1999; 22:268-272.
26. Pellarchy S, Jones L, Hood J. Computerized detection of potential drug-enteral nutrition product problems [Letter]. Am J Hosp Pharm 1994; 51:704.
27. Pepin SM. Databases of potential drug-enteral nutrition product interactions [Letter]. Am J Hosp Pharm 1994; 51:1965.
28. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf 2000; 22:53-72.